NAION
-
FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition
* NAION cases have been reported for all currently marketed GLP-1 RA products. FDA concluded that there is a potential increased risk of rare NAION events in patients taking GLP-1 RAs. Based on these findings, FDA is requiring that application holders add information about the risk for NAION to...- madman
- Thread
- fda Glp-1ras loss of vision NAION safety
- Replies: 1
- Forum: General Peptide Use & Information
Beyond Testosterone Podcast
Sponsors
NAION
